Evidence map›Paper›PMID 36212421›Full record

ArticleFrontiers in oncology2022

5-ALA-guided tumor resection during awake speech mapping in gliomas located in eloquent speech areas: Single-center experience.

Sergey A Goryaynov, Svetlana B Buklina, Ivan V Khapov, Artyom I Batalov, Alexander A Potapov, Igor N Pronin, Artem U Belyaev, Andrey A Aristov, Vadim U Zhukov, Galina V Pavlova and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Sergey A GoryaynovDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Svetlana B BuklinaDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Ivan V KhapovI.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Artyom I BatalovDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Alexander A PotapovDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Igor N ProninDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Artem U BelyaevDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Andrey A AristovDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Vadim U ZhukovDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Galina V PavlovaDepartments of Neurotraumatology and Neurooncology, N.N.Burdenko National Medical Research Center of Neurosurgery, Moscow, Russia.
Evgenii BelykhDepartment of Neurosurgery, New Jersey Medical School, Rutgers University, New Jersey, NJ, United States.
Burdenko Neurosurgery Institute · RUInstitute of Higher Nervous Activity and Neurophysiology · RURutgers, The State University of New Jersey · USSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Achieving maximal functionally safe resection of gliomas located within the eloquent speech areas is challenging, and there is a lack of literature on the combined use of 5-aminolevulinic acid (5-ALA) guidance and awake craniotomy. Objective: The aim of this study was to describe our experience with the simultaneous use of 5-ALA fluorescence and awake speech mapping in patients with left frontal gliomas located within the vicinity of eloquent speech areas. Materials and methods: A prospectively collected database of patients was reviewed. 5-ALA was administered at a dose of 20 mg/kg 2 h prior to operation, and an operating microscope in BLUE400 mode was used to visualize fluorescence. All patients underwent surgery using the "asleep-awake-asleep" protocol with monopolar and bipolar electrical stimulation to identify the proximity of eloquent cortex and white matter tracts and to guide safe limits of resection along with fluorescence guidance. Speech function was assessed by a trained neuropsychologist before, during, and after surgery. Results: In 28 patients operated with cortical mapping and 5-ALA guidance (12 Grade 4, 6 Grade 3, and 10 Grade 2 gliomas), Broca's area was identified in 23 cases and Wernicke's area was identified in 5 cases. Fluorescence was present in 14 cases. Six tumors had residual fluorescence due to the positive speech mapping in the tumor bed. Transient aphasia developed in 14 patients, and permanent aphasia developed in 4 patients. In 6 patients operated with cortical and subcortical speech mapping and 5-ALA guidance (4 Grade 4, 1 Grade 3, and 1 Grade 2 gliomas), cortical speech areas were mapped in 5 patients and subcortical tracts were encountered in all cases. In all cases, resection was stopped despite the presence of residual fluorescence due to speech mapping findings. Transient aphasia developed in 6 patients and permanent aphasia developed in 4 patients. In patients with Grade 2-3 gliomas, targeted biopsy of focal fluorescence areas led to upgrading the grade and thus more accurate diagnosis. Conclusion: 5-ALA guidance during awake speech mapping is useful in augmenting the extent of resection for infiltrative high-grade gliomas and identifying foci of anaplasia in non-enhancing gliomas, while maintaining safe limits of functional resection based on speech mapping. Positive 5-ALA fluorescence in diffuse Grade 2 gliomas may be predictive of a more aggressive disease course.

Indexed as

5-ALAarcuate fasciculusawake craniotomyfiber tractsfluorescencegliomasuperior longitudinal fasciculus

Identifiers

PMID36212421
PMCPMC9538677
OpenAlexW4296836407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.